Biohaven Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.6%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
-$2.64next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, marketable securities and restricted cash Quarterly351.8M
R&D Expenses (Quarterly) Quarterly103.8M
G&A Expenses (Quarterly) Quarterly26.6M
Watch Items
- Pivotal epilepsy program with selective Kv7 ion channel activator, opakalimTrigger: Expected topline results in 2H 2026
- Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfaTrigger: Topline data expected in 2H 2026
- Pivotal trials of BHV-1400 (Gd-IgA1 TRAP degrader) in IgA nephropathy (IgAN) and BHV-1300 (IgG MoDE degrader) in Graves' diseaseTrigger: Expected to initiate by mid-year 2026
Research as of 20 Jun 2026